Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution The report provides in-depth analysis of drivers and barriers that impact the global cardiovascular disorders market. The report analyzes the generics market for cardiovascular disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns are forecast until 2018 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GBI Research’s team of industry experts. The global generics market cardiovascular drugs is expected to grow rapidly due to the growing dyslipdemia, thrombosis and hypertension populations in the developed countries, as well as patent expiries of major blockbusters such as Lipitor (atorvastatin), Plavix (clopidigrel) and Diovan (valsartan). The patent expiries of these blockbuster drugs will trigger generic competition in the cardiovascular therapeutics market, making it more competitive. In 2010, the generics market for cardiovascular drugs was estimated at $20.5 billion, indicating a year on year decline of 0.9% from 2004-2010. Patent expiries of the leading antiplatelets/antithrombotics such as Plavix (clopidigrel) and Lovenox (enoxaparin) and lipid lowering blockbuster Lipitor in 2010-2012, resulting in uptake of generics, is expected to cause the market to increase significantly from 2010 to 2018. Buy your copy of this report @ http://www.reportsnreports.com/reports/160378generics-in-cardiovascular-diseases-market-to-2018-loss-of-lipitor-marketexclusivities-and-impending-patent-expirations-of-plavix-to-drive-genericsubstitution.html Scope Annualized market data for the generics in cardiovascular disorders market from 2004 to 2010, forecast forward to 2018. Analysis of the leading therapeutic segments, including pulmonary arterial hypertension, thrombosis, dyslipidemia, hypertension, coronary artery disease, and Angina Pectoris. Analysis of the generics in cardiovascular disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan. Market characterization of the generics in cardiovascular disorders market, including market size, annual cost of treatment and treatment usage pattern. Key drivers and barriers that have a significant impact on the generics market. Coverage of pipeline molecules in various phases of drug development. Competitive benchmarking of leading generic companies. The key companies studied in this report are Key M&A activities, licensing agreements that have taken place from 2004 to 2011 in the global cardiovascular disorders market.
Major points covered in Table of Contents of this report include: 1 Table of Contents 2 Generics in Cardiovascular Diseases Market to 2018 – Executive Summary 3 Generics in Cardiovascular Diseases Market to 2018 – Introduction 4 Generics in Cardiovascular Diseases Market to 2018 – Global Market Overview 5 Generics in Cardiovascular Disease Market to 2018 - Geographical Landscape 6 Generics in Cardiovascular Diseases Market to 2018: Therapeutic Landscape 7 Generics in Cardiovascular Diseases Market to 2018 – Product Pipeline Analysis 8 Generics in Cardiovascular Diseases Market to 2018 – Most Promising Pipeline Molecules 9 Generics in Cardiovascular Diseases Market to 2018 – Competitive Landscape 10 Generics in Cardiovascular Diseases Market to 2018 – Strategic Consolidations 11 Generics in Cardiovascular Diseases Market to 2018 – Appendix List of Tables List of Figures
Browse reports related to Pharmaceuticals @ http://www.reportsnreports.com/market-research/pharmaceuticals/
Report Details: Published: May 2012 No. of Pages: 129 Price: Single User License – US$3500
Corporate User License – US$10500
Contact: Priyank Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 sales@reportsandreports.com Connect With Us: